<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2017.74043</article-id><article-id pub-id-type="publisher-id">ACM-22447</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20170400000_98028467.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  泰山玉竹多糖对小鼠糖尿病的治疗作用及细胞免疫机制研究
  Effect and Cellular Immunological Mechanism on Mice of Diabetes with Extraction of Polysaccharide from Taishan Polygonatum odoratum
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郭</surname><given-names>珊珊</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>雪</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>宁宁</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>修</surname><given-names>鹏程</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>null</addr-line></aff><aff id="aff2"><addr-line>泰山医学院，山东 泰安</addr-line></aff><pub-date pub-type="epub"><day>25</day><month>09</month><year>2017</year></pub-date><volume>07</volume><issue>04</issue><fpage>258</fpage><lpage>263</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：研究泰山玉竹提取物玉竹多糖(EA-PAOA)对I型糖尿病小鼠的降血糖作用及可能的细胞免疫学机制。方法：采用常规的链脲佐菌素(STZ)多次注射诱导法制备I型糖尿病小鼠模型，试验组分低、中、高三个剂量灌胃等体积的EA-PAOA，对照组灌胃等体积的生理盐水。于用药后1~4周每周检测各组小鼠血糖和胰岛素水平；通过流式细胞仪检测外周血CD4
   <sup>+</sup>T细胞和CD8
   <sup>+</sup>T细胞比例，采用酶联免疫吸附实验(ELISA)检测血清Th1型细胞因子γ干扰素(IFN-γ)和Th2型细胞因子白细胞介素4 (IL-4)浓度。最后进行数据的统计学分析。结果：与模型组相比，实验组空腹血糖水平显著降低(P &lt; 0.05~0.01)；胰岛素水平则显著升高(P &lt; 0.01)；外周血CD4
   <sup>+</sup>T细胞比例显著降低而CD8
   <sup>+</sup>T细胞比例显著降低(P &lt; 0.01)，CD4
   <sup>+</sup>/CD8
   <sup>+</sup>比例显著降低(P &lt; 0.01)。血清中Th1型细胞因子IFN-γ显著降低(P &lt; 0.05~0.01)，而Th2型细胞因子IL-4显著升高(P &lt; 0.05~0.01)。结论：泰山玉竹多糖治疗能明显降低1型糖尿病小鼠血糖，其降糖作用可能通过调节糖尿病小鼠T细胞亚群及Th1型和Th2型细胞因子水平而发挥的。
    Objective: To study the therapeutic effects of extraction from Polygonatum odoratum (EA-PAOA) from Taishan on type 1 diabetes and the possible immunological mechanism. Methods: Diabetic mouse models were established by repeated injection of small dosage of STZ. Mice were divided into 3 different groups according to different concentrations of EA-PAOA which were administrated by intragastric. The control group was administrated the same volume saline by intragastric. Changes of blood glucose, insulin were monitored from 1 to 4 weeks after administration. Changes of levels of serum interferon γ (IFN-γ) and interleukin-4(IL-4) in diabetic mouse were tested with enzyme- linked immunosorbent assay (ELISA) after administration. Finally, data were analyzed by statistic method. Results: Levels of blood glucose were significantly lower after administration in all extrac-tion groups than that in the model group (P &lt; 0.05 - 0.01). Levels of insulin were significantly higher after administration in all extraction groups than that in the model group (P &lt; 0.01). In the periph-eral blood, CD4
   <sup>+</sup> T cells were significantly decreased, whereas CD8
   <sup>+</sup> T cells were significantly in-creased (P &lt; 0.01), and the ratio of CD4
   <sup>+</sup>/CD8
   <sup>+</sup> was significantly decreased (P &lt; 0.05 - 0.01). Levels of type 1 cytokine IFN-γ were lower in each extraction groups than that in the model group, whereas levels of type 2 cytokine IL-4 were significantly higher in each extraction groups than that in the model group (P &lt; 0.05 - 0.01). Conclusion: EA-PAOA can markedly decrease the blood glucose of the in mice with diabetes. The mechanisms were probably related to regulating of T cell subsets. 
  
 
</p></abstract><kwd-group><kwd>泰山玉竹多糖，1型糖尿病，细胞免疫, Extraction Form Taishan Polygonatum odoratum (EA-PAOA)</kwd><kwd> Type 1 Diabetes</kwd><kwd> Cellular Immunity</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>泰山玉竹多糖对小鼠糖尿病的治疗作用及 细胞免疫机制研究<sup> </sup></title><p>郭珊珊，张雪，刘宁宁，修鹏程</p><p>泰山医学院，山东 泰安</p><p>收稿日期：2017年9月30日；录用日期：2017年10月19日；发布日期：2017年10月25日</p><disp-formula id="hanspub.22447-formula8"><graphic xlink:href="//html.hanspub.org/file/10-1570392x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：研究泰山玉竹提取物玉竹多糖(EA-PAOA)对I型糖尿病小鼠的降血糖作用及可能的细胞免疫学机制。方法：采用常规的链脲佐菌素(STZ)多次注射诱导法制备I型糖尿病小鼠模型，试验组分低、中、高三个剂量灌胃等体积的EA-PAOA，对照组灌胃等体积的生理盐水。于用药后1~4周每周检测各组小鼠血糖和胰岛素水平；通过流式细胞仪检测外周血CD4<sup>+</sup>T细胞和CD8<sup>+</sup>T细胞比例，采用酶联免疫吸附实验(ELISA)检测血清Th1型细胞因子γ干扰素(IFN-γ)和Th2型细胞因子白细胞介素4 (IL-4)浓度。最后进行数据的统计学分析。结果：与模型组相比，实验组空腹血糖水平显著降低(P &lt; 0.05~0.01)；胰岛素水平则显著升高(P &lt; 0.01)；外周血CD4<sup>+</sup>T细胞比例显著降低而CD8<sup>+</sup>T细胞比例显著降低(P &lt; 0.01)，CD4<sup>+</sup>/CD8<sup>+</sup>比例显著降低(P &lt; 0.01)。血清中Th1型细胞因子IFN-γ显著降低(P &lt; 0.05~0.01)，而Th2型细胞因子IL-4显著升高(P &lt; 0.05~0.01)。结论：泰山玉竹多糖治疗能明显降低1型糖尿病小鼠血糖，其降糖作用可能通过调节糖尿病小鼠T细胞亚群及Th1型和Th2型细胞因子水平而发挥的。</p><p>关键词 :泰山玉竹多糖，1型糖尿病，细胞免疫</p><disp-formula id="hanspub.22447-formula9"><graphic xlink:href="//html.hanspub.org/file/10-1570392x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2017 by authors and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/10-1570392x7_hanspub.png" /> <img src="//html.hanspub.org/file/10-1570392x8_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>I型糖尿病是一种T细胞介导的慢性自身免疫性疾病，免疫系统选择性攻击胰岛β细胞，导致β细胞的损伤以及胰岛素的绝对缺乏。主要表现为多饮、多食、多尿、消瘦、疲乏无力以及血糖增高等症状 [<xref ref-type="bibr" rid="hanspub.22447-ref1">1</xref>] 。目前，糖尿病的治疗主要以降糖为主，存在一定的毒副作用，有待开发新的无毒副作用的新药并探讨相关的作用机制，为糖尿病的治疗提供新的备选药物。玉竹被《神农本草经》列为上品，含有多糖、甾族化合物、糖苷等成分。其多糖成分玉竹多糖(EA-PAOA)具有一定的降血糖、降血脂、提高免疫力等功效，国内已有学者研究表明其对链脲佐菌素(STZ)诱导的糖尿病小鼠具有降低血糖的作用 [<xref ref-type="bibr" rid="hanspub.22447-ref2">2</xref>] ，但其免疫学作用机制并不十分清楚。STZ对动物胰岛β细胞有特异性的破坏作用，是近几年使用最广泛的糖尿病动物模型化学诱导剂 [<xref ref-type="bibr" rid="hanspub.22447-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.22447-ref3">3</xref>] 。泰山玉竹有其独特的生长环境，本文通过建立STZ诱导的1型糖尿病小鼠模型，探讨泰山玉竹多糖EA-PAOA对糖尿病小鼠的降糖作用及免疫机理。</p></sec><sec id="s4"><title>2. 材料与方法</title><sec id="s4_1"><title>2.1. 药材与主要试剂</title><p>玉竹，产于泰山，由泰安金泰联大药店提供。链脲佐菌素(STZ) (Sigma公司)，小鼠IFN-γ和IL-4 ELISA试剂盒(美国eBioscience公司)，胰岛素放免分析试剂盒(上海西唐科技公司)。</p></sec><sec id="s4_2"><title>2.2. 主要仪器</title><p>流式细胞仪(Aria II, BD公司)，Touch血糖仪(迈瑞公司)，酶标仪(Tecan Infinite F200/M200型，瑞士)。旋转蒸发仪(RE-52AA型，上海予华公司)。</p></sec><sec id="s4_3"><title>2.3. 小鼠</title><p>C57BL/6小鼠，雄性，50只，8 w龄(北京维通利华公司提供)。</p></sec><sec id="s4_4"><title>2.4. 方法</title><sec id="s4_4_1"><title>2.4.1. 泰山玉竹多糖的提取</title><p>取泰山玉竹，洗净粉碎后，以30%乙醇常温浸提24 h，G4过滤分离，旋转蒸发仪蒸发回收乙醇，得黄棕色沉淀，于烘箱干燥后成浸膏，即为中性多糖成分。使用前配制成所需浓度的溶液。</p></sec><sec id="s4_4_2"><title>2.4.2. 动物模型的制备及分组</title><p>将50只8 w龄健康的雄性C57BL/6小鼠随机分成五组，每组10只小鼠。正常对照组、糖尿病模型组、三个剂量实验组。正常对照组小鼠只注射等体积的枸橼酸钠缓冲液，其余小鼠应用0.1 mol/l枸橼酸钠缓冲液(PA 4.4)配制成0.4%链脲佐菌素(STZ)溶液，按40 mg/kg剂量进行腹腔注射，每天1次，连续5天制备糖尿病模型。药物处理方法如下，正常对照组与糖尿病对照组，灌胃0.2 ml生理盐水，每日1次，共4周；实验组采用玉竹多糖EA-PAOA的1 g/kg为基础给药量，另取5倍、10倍量，即EA-PAOA低剂量组(1 g/kg)、EA-PAOA中剂量组(5 g/kg)、EA-PAOA高剂量组(10 g/kg)分别以等体积的0.2 ml进行灌胃，每日1次，共4周。本研究相关动物实验得到泰山医学院动物伦理委员会的许可。</p></sec><sec id="s4_4_3"><title>2.4.3. 血糖、胰岛素、T细胞亚群、细胞因子检测</title><p>血糖及胰岛素含量检测：对各组小鼠每周分别测血糖及胰岛素含量，动态监测1型糖尿病模型建立。在注射STZ 72小时后，血糖稳定升高，出现多食、多饮、多尿的三多症状。最终以血糖 ≥ 11.1 mmol/L以上2周，为造模成功 [<xref ref-type="bibr" rid="hanspub.22447-ref4">4</xref>] 。</p><p>空腹血糖测定：割尾法于尾静脉采血1滴，采用血糖快速检测仪进行血糖检测。用药前及用药过程每周检测1次，共5次。</p><p>CD4<sup>+</sup>T细胞和CD8<sup>+</sup>T细胞亚群检测：眼眶取血1滴，肝素钠抗凝，加入Rat-anti-mouse CD4和CD8单抗标记15 min，红细胞裂解液ACK裂红15 min，加入1 ml 0.01M PBS，3000 rpm离心5 min，加入300 μl PBS定容，进行流式细胞仪检测，结果以各亚群占淋巴细胞的百分比表示。</p><p>ELISA检测细胞因子：小鼠用摘眼球法取血，离心分离血清，置−20℃保存。采用酶联免疫吸附实验(Enzyme linked immuosorbent assay, ELISA)测定各组标本干扰素γ (interferon γ, IFN-γ)和白细胞介素4 (interleukin 4, IL-4)水平，操作方法按照试剂盒说明书进行。</p></sec><sec id="s4_4_4"><title>2.4.4. 统计学分析</title><p>采用SPSS 17.0软件系统进行分析，实验数据用均数&#177;标准差(x &#177; s)表示，组间比较采用单因素方差分析，以P &lt; 0.05为差异具有统计学意义。</p></sec></sec></sec><sec id="s5"><title>3. 结果</title><p>实验组空腹血糖水平比模型组显著降低(P &lt; 0.05~0.01)，胰岛素水平则有明显升高(P &lt; 0.05)，细胞因子IFN-γ，实验组较模型组显著低(P &lt; 0.05~0.01)。细胞因子IL-4实验组较模型组显著升高(P &lt; 0.05~0.01)。各项检测指标检测结果见表1~4。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> The effect of EA-PAOA on the blood glucose level of STZ mice (x &#177; s, mmol/L</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="2"   rowspan="2"  >用药前</th><th align="center" valign="middle"  colspan="4"  >用药后</th></tr></thead><tr><td align="center" valign="middle" >1周</td><td align="center" valign="middle" >2周</td><td align="center" valign="middle" >3周</td><td align="center" valign="middle" >4周</td></tr><tr><td align="center" valign="middle" >正常对照组</td><td align="center" valign="middle" >5.94 &#177; 0.83</td><td align="center" valign="middle" >5.94 &#177; 0.77</td><td align="center" valign="middle" >5.95 &#177; 0.49</td><td align="center" valign="middle" >5.85 &#177; 0.73</td><td align="center" valign="middle" >5.65 &#177; 0.56</td></tr><tr><td align="center" valign="middle" >模型组</td><td align="center" valign="middle" >23.50 &#177; 1.34</td><td align="center" valign="middle" >24.26 &#177; 1.35</td><td align="center" valign="middle" >24.55 &#177; 1.18</td><td align="center" valign="middle" >24.80 &#177; 1.44</td><td align="center" valign="middle" >25.18 &#177; 1.26</td></tr><tr><td align="center" valign="middle" >EA-PAOA低剂量组</td><td align="center" valign="middle" >23.63 &#177; 2.78</td><td align="center" valign="middle" >18.48 &#177; 2.41<sup>#</sup></td><td align="center" valign="middle" >16.45 &#177; 2.34<sup>##</sup></td><td align="center" valign="middle" >14.30 &#177; 1.92<sup>##</sup></td><td align="center" valign="middle" >12.83 &#177; 1.74<sup>##</sup></td></tr><tr><td align="center" valign="middle" >EA-PAOA中剂量组</td><td align="center" valign="middle" >23.18 &#177; 1.65</td><td align="center" valign="middle" >16.67 &#177; 1.58<sup>#</sup></td><td align="center" valign="middle" >13.76 &#177; 2.01<sup>##</sup></td><td align="center" valign="middle" >11.78 &#177; 1.02<sup>##</sup></td><td align="center" valign="middle" >10.15 &#177; 0.75<sup>##</sup></td></tr><tr><td align="center" valign="middle" >EA-PAOA高剂量组</td><td align="center" valign="middle" >23.71 &#177; 2.81</td><td align="center" valign="middle" >17.17 &#177; 2.93<sup>#</sup></td><td align="center" valign="middle" >15.28 &#177; 2.62<sup>##</sup></td><td align="center" valign="middle" >13.35 &#177; 1.98<sup>##</sup></td><td align="center" valign="middle" >11.74 &#177; 1.26<sup>##</sup></td></tr></tbody></table></table-wrap><p>表1. EA-PAOA对各组STZ小鼠血糖水平的影响(x &#177; s, mmol/L)</p><p>注：<sup>#</sup>P &lt; 0.05, <sup>##</sup>P &lt; 0.01 vs模型组</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> The effect of EA-PAOA on insulin in STZ mice (x &#177; s, mmol/L</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="2"   rowspan="2"  >用药前</th><th align="center" valign="middle"  colspan="4"  >用药后</th></tr></thead><tr><td align="center" valign="middle" >1周</td><td align="center" valign="middle" >2周</td><td align="center" valign="middle" >3周</td><td align="center" valign="middle" >4周</td></tr><tr><td align="center" valign="middle" >正常对照组</td><td align="center" valign="middle" >51.24 &#177; 10.92</td><td align="center" valign="middle" >52.45 &#177; 9.19</td><td align="center" valign="middle" >52.37 &#177; 10.10</td><td align="center" valign="middle" >5243 &#177; 10.06</td><td align="center" valign="middle" >52.16 &#177; 10.55</td></tr><tr><td align="center" valign="middle" >模型组</td><td align="center" valign="middle" >19.69 &#177; 5.71</td><td align="center" valign="middle" >19.71 &#177; 6.02</td><td align="center" valign="middle" >19.87 &#177; 5.93</td><td align="center" valign="middle" >19.72 &#177; 4.51</td><td align="center" valign="middle" >19.88 &#177; 5.32</td></tr><tr><td align="center" valign="middle" >EA-PAOA低剂量组</td><td align="center" valign="middle" >19.70 &#177; 5.67</td><td align="center" valign="middle" >44.62 &#177; 11.51<sup>##</sup></td><td align="center" valign="middle" >41.47 &#177; 12.71<sup>##</sup></td><td align="center" valign="middle" >37.50 &#177; 13.05<sup>##</sup></td><td align="center" valign="middle" >36.50 &#177; 13.22<sup>##</sup></td></tr><tr><td align="center" valign="middle" >EA-PAOA中剂量组</td><td align="center" valign="middle" >19.82 &#177; 5.79</td><td align="center" valign="middle" >46.59 &#177; 12.16<sup>##</sup></td><td align="center" valign="middle" >43.54 &#177; 11.62<sup>##</sup></td><td align="center" valign="middle" >40.53 &#177; 11.78<sup>##</sup></td><td align="center" valign="middle" >34.52 &#177; 12.33<sup>##</sup></td></tr><tr><td align="center" valign="middle" >EA-PAOA高剂量组</td><td align="center" valign="middle" >19.81 &#177; 5.68</td><td align="center" valign="middle" >47.02 &#177; 11.92<sup>##</sup></td><td align="center" valign="middle" >43.98 &#177; 12.31<sup>##</sup></td><td align="center" valign="middle" >40.99 &#177; 11.53<sup>##</sup></td><td align="center" valign="middle" >36.92 &#177; 11.55<sup>##</sup></td></tr></tbody></table></table-wrap><p>表2. EA-PAOA对各组STZ小鼠胰岛素的影响(x &#177; s, mmol/L)</p><p>注：<sup>##</sup>P &lt; 0.01 vs模型组</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Comparation of peripheral blood T lymphocyte subsets in EA-PAOA group and model group (x &#177; s, %</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >CD4<sup>+</sup>T</th><th align="center" valign="middle" >CD8<sup>+</sup>T</th><th align="center" valign="middle" >CD4<sup>+</sup>T/CD8<sup>+</sup>T</th></tr></thead><tr><td align="center" valign="middle" >模型组(n = 20)</td><td align="center" valign="middle" >64.13 &#177; 9.27</td><td align="center" valign="middle" >32.24 &#177; 7.66</td><td align="center" valign="middle" >2.052 &#177; 0.722</td></tr><tr><td align="center" valign="middle" >EA-PAOA组(n = 20)</td><td align="center" valign="middle" >37.93 &#177; 6.10<sup>##</sup></td><td align="center" valign="middle" >61.17 &#177; 5.47<sup>##</sup></td><td align="center" valign="middle" >0.672 &#177; 0.212<sup>##</sup></td></tr></tbody></table></table-wrap><p>表3. EA-PAOA对组和模型组外周血T细胞亚群的比较(x &#177; s, %)</p><p>注：<sup>##</sup>P &lt; 0.01 vs模型组</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> The effect of EA-PAOA on the levels of serum cytokines IFN-γ and IL-4 in STZ mice (x &#177; s, mmol/L</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >IFN-γ</th><th align="center" valign="middle" >IL-4</th></tr></thead><tr><td align="center" valign="middle" >正常对照组</td><td align="center" valign="middle" >73.21 &#177; 10.15</td><td align="center" valign="middle" >49.38 &#177; 5.88</td></tr><tr><td align="center" valign="middle" >模型组</td><td align="center" valign="middle" >159.82 &#177; 4.51</td><td align="center" valign="middle" >31.51 &#177; 5.37</td></tr><tr><td align="center" valign="middle" >EA-PAOA低剂量组(1 g/kg)</td><td align="center" valign="middle" >137.43 &#177; 9.63<sup>#</sup></td><td align="center" valign="middle" >39.52 &#177; 6.35<sup>#</sup></td></tr><tr><td align="center" valign="middle" >EA-PAOA中剂量组</td><td align="center" valign="middle" >89.38 &#177; 7.74<sup>##</sup></td><td align="center" valign="middle" >48.93 &#177; 10.19<sup>##</sup></td></tr><tr><td align="center" valign="middle" >EA-PAOA高剂量组</td><td align="center" valign="middle" >54.57 &#177; 5.64<sup>##</sup></td><td align="center" valign="middle" >58.19 &#177; 5.33<sup>##</sup></td></tr></tbody></table></table-wrap><p>表4. EA-PAOA对各组STZ小鼠血清细胞因子IFN-γ和IL-4水平的影响 (x &#177; s, mmol/L)</p><p>注：<sup>#</sup>P &lt; 0.05, <sup>##</sup>P &lt; 0.01 vs模型组</p></sec><sec id="s6"><title>4. 讨论</title><p>链脲佐菌素(STZ)是一种含有亚硝基的化合物，能够破坏胰岛β细胞，大量的β细胞被破坏导致胰岛素原的合成障碍，从而导致糖尿病，因此常被广泛用于糖尿病的化学诱导 [<xref ref-type="bibr" rid="hanspub.22447-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.22447-ref3">3</xref>] 。本研究利用STZ诱导法成功制备出小鼠1型糖尿病模型，并通过泰山玉竹多糖治疗探讨其对糖尿病的治疗作用及可能的免疫作用机理。结果表明(表1)，泰山玉竹多糖(EA-PAOA)试验组与模型对照组相比，各个剂量组小鼠的血糖明显降低，证实玉竹多糖有显著的降血糖作用，但各剂量组之间差异并不显著，表明泰山玉竹多糖的降糖作用无明显的剂量依赖性。从本实验结果表2可见，泰山玉竹多糖使小鼠血糖显著降低的同时，也使胰岛素水平明显升高，说明玉竹多糖对STZ引起的胰岛β细胞破坏具有一定的抑制作用，通过增强胰岛素的敏感性而发挥降血糖作用 [<xref ref-type="bibr" rid="hanspub.22447-ref5">5</xref>] 。</p><p>细胞免疫在1型糖尿病的发病机制中发挥了重要作用，其特征表现为CD4<sup>+</sup>T和CD8<sup>+</sup>T淋巴细胞在胰岛的浸润引起的胰岛炎，选择性的损伤胰岛β细胞，导致胰岛素分泌降低或缺乏 [<xref ref-type="bibr" rid="hanspub.22447-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.22447-ref6">6</xref>] 。本实验结果表明，在对照组小鼠的外周血存在CD4<sup>+</sup>T细胞比例增多、CD8<sup>+</sup>T细胞数目减少、及CD4<sup>+</sup>/CD8<sup>+</sup>T细胞比例升高导致的细胞免疫功能低下；而在EA-PAOA预处理的小鼠外周血中以CD8<sup>+</sup>T细胞亚群为主，CD4<sup>+</sup>/CD8<sup>+</sup>T亚群比例下降，提示纠正CD4<sup>+</sup>/CD8<sup>+</sup>T细胞比例失衡可能参与了EA-PAOA治疗小鼠糖尿病的作用机制。</p><p>正常机体中各T淋巴细胞亚群之间会相互作用维持着机体正常免疫功能。根据分泌的细胞因子不同，CD4<sup>+</sup>T淋巴细胞分为Th1和Th2亚群 [<xref ref-type="bibr" rid="hanspub.22447-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.22447-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.22447-ref9">9</xref>] 。Th1细胞通过分泌细胞因子IFN-γ)抑制Th2细胞的功能，并可以通过活化巨噬细胞以及促进迟发性超敏反应，对胰岛β细胞具有直接的细胞毒性，加重胰岛炎的程度，促进1型糖尿病的发生；反之，Th2细胞通过分泌IL-4抑制Th1细胞的增殖，对胰岛细胞起到保护作用。本研究结果显示，与模型组相比，EA-PAOA各组IFN-γ显著降低且呈现明显的剂量依赖性；IL-4水平有不同程度的升高且随着剂量的增大，升高更明显。推测EA-PAOA可能通过改变Th1和Th2细胞的平衡而发挥治疗糖尿病的作用。通过EA-PAOA各剂量组的血糖、胰岛素、血清IFN-γ和IL-4水平变化结果发现，尽管某些指标如血糖值5 g/kg组与10 g/kg组比较无明显差异，但其他指标一般都呈现高剂量组效果好于低剂量组，即呈现出明显剂量效应依赖关系，本研究结果与文献报道较一致且又有明显的方法上的改进 [<xref ref-type="bibr" rid="hanspub.22447-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.22447-ref2">2</xref>] 。</p><p>综上所述，泰山玉竹多糖通过调节细胞免疫平衡，发挥了对1型糖尿病的治疗作用，而且具有毒性低、制备方便等优点，可望用于I型糖尿病的临床治疗。</p></sec><sec id="s7"><title>基金项目</title><p>基金号：201510439096，2015年国家级大学生创新训练计划。</p></sec><sec id="s8"><title>文章引用</title><p>郭珊珊,张 雪,刘宁宁,修鹏程. 泰山玉竹多糖对小鼠糖尿病的治疗作用及细胞免疫机制研究 Effect and Cellular Immunological Mechanism on Mice of Diabetes with Extraction of Polysaccharide from Taishan Polygonatum odoratum[J]. 临床医学进展, 2017, 07(04): 258-263. http://dx.doi.org/10.12677/ACM.2017.74043</p></sec><sec id="s9"><title>参考文献 (References)</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.22447-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">张立新, 庞维, 付京晶, 等. 玉竹对STZ诱导的1型糖尿病小鼠的降糖作用中药药理与临床[J]. 2012, 28(2): 106-108.</mixed-citation></ref><ref id="hanspub.22447-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">刘燊, 胡彦君. 玉竹提取物玉竹多糖对 1型糖尿病小鼠的作用研究[J]. 广州医药, 2009, 40(6): 49-52.</mixed-citation></ref><ref id="hanspub.22447-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Al-Awar, A., Kupai, K., Veszelka, M., et al. (2016) Experimental Diabetes Mellitus in Different Animal Models. Journal of Diabetes Research, 2016, Article ID: 9051426. &lt;br&gt;https://doi.org/10.1155/2016/9051426</mixed-citation></ref><ref id="hanspub.22447-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Sun, W., Wang, L.Y., Zhang, Z.M., et al. (2003) Intramuscular Transfer of Naked Calcitonin Gene-Related Peptide Gene Prevents Autoimmune Diabetes Induced by Multiple Low-Dose Streptozotocin in C57BL Mice. European Journal of Immunology, 33, 233-242. &lt;br&gt;https://doi.org/10.1002/immu.200390026</mixed-citation></ref><ref id="hanspub.22447-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Kulshrestha, D., Yeh, L.T., Chien, M.W., et al. (2017) Peripheral Autoimmune Regulator Induces Exhaustion of CD4+ and CD8+ Effector T Cells to Attenuate Autoimmune Diabetes in Non-Obese Diabetic Mice. Frontiers in Immunology, 8, 1128. &lt;br&gt;https://doi.org/10.3389/fimmu.2017.01128</mixed-citation></ref><ref id="hanspub.22447-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Walker, L.S. and von Herrath, M. (2016) CD4 T Cell Differenti-ation in Type 1 Diabetes. Clinical &amp; Experimental Immunology, 183, 16-29. &lt;br&gt;https://doi.org/10.1111/cei.12672</mixed-citation></ref><ref id="hanspub.22447-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Kumar, N.P., Moideen, K., George, P.J., et al. (2016) Coincident Diabetes Mellitus Modulates Th1-, Th2-, and Th17-Cell Responses in Latent Tuberculosis in an IL-10- and TGF-Beta-Dependent Manner. European Journal of Immunology, 46, 390-399. &lt;br&gt;https://doi.org/10.1002/eji.201545973</mixed-citation></ref><ref id="hanspub.22447-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Nekoua, M.P., Fachinan, R., Atchamou, A.K., Nouatin, O., Amoussou-Guenou, D., Amoussou-Guenou, M.K., Moutairou, K. and Yessoufou, A. (2016) Modulation of Immune Cells and Th1/Th2 Cytokines in Insulin-Treated Type 2 Diabetes Mellitus. African Health Sciences, 16, 712-724. &lt;br&gt;https://doi.org/10.4314/ahs.v16i3.11</mixed-citation></ref><ref id="hanspub.22447-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Vaseghi, H. and Jadali, Z. (2016) Th1/Th2 Cytokines in Type 1 Diabetes: Relation to Duration of Disease and Gender. Indian Journal of Endocrinology and Metabolism, 20, 312-316. &lt;br&gt;https://doi.org/10.4103/2230-8210.180002</mixed-citation></ref></ref-list></back></article>